Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular mechanism of SLC5A8 inactivation in breast cancer.

Molecular and cellular biology - 1 Oct 2013

Elangovan Selvakumar, Pathania Rajneesh, Ramachandran Sabarish, Ananth Sudha, Padia Ravi N, Srinivas Sonne R, Babu Ellappan, Hawthorn Lesleyann, Schoenlein Patricia V, Boettger Thomas, Smith Sylvia B, Prasad Puttur D, Ganapathy Vadivel, Thangaraju Muthusamy

Abstract excerpt

SLC5A8 is a putative tumor suppressor that is inactivated in more than 10 different types of cancer, but neither the oncogenic signaling responsible for SLC5A8 inactivation nor the functional relevance of SLC5A8 loss to tumor growth has been elucidated. Here, we identify oncogenic HRAS (HRAS(G12V)) as a potent mediator of SLC5A8 silencing in human nontransformed normal mammary epithelial cell lines and in mouse...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA (Cytosine-5-)-Methyltransferase 1
Share to Carcinogenesis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cation Transport Proteins

Share to DNA (Cytosine-5-)-Methyltransferases

Share to HCT116 Cells

Share to MCF-7 Cells

Share to Monocarboxylic Acid Transporters

Share to Transplantation, Heterologous

Source

Open in PubMed Open full text

Identifiers

PMID: 23918800
DOI: 10.1128/MCB.01702-12
PMCID: PMC3811868

Genes

HRAS
DNMT1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular mechanism of SLC5A8 inactivation in breast cancer.PMID 23918800Read ↗

Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver GenesSemantic proximity Read ↗

Renal medullary carcinomas depend upon <i>SMARCB1</i> loss and are sensitive to proteasome inhibitionSemantic proximity Read ↗

Targeting EMSY-mediated methionine metabolism is a potential therapeutic strategy for triple-negative breast cancerSemantic proximity Read ↗

CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast CancerSemantic proximity Read ↗

Invasive lobular carcinoma integrated multi-omics analysis reveals silencing of Arginosuccinate synthase and upregulation of nucleotide biosynthesis in tamoxifen resistanceSemantic proximity Read ↗

Expression of the non-coding RNA nc886 facilitates the development of tyrosine kinase inhibitor resistance in EGFR-mutated non-small-cell lung cancer cells.Semantic proximity Read ↗

SMARCA4 Inhibits Breast Cancer Progression and Metastasis through RHOA SuppressionSemantic proximity Read ↗

Loss of SUV420H2 promotes EGFR inhibitor resistance in NSCLC through upregulation of MET via LINC01510Semantic proximity Read ↗

Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibitionSemantic proximity Read ↗

The effects and mechanisms of SLC34A2 on tumorigenicity in human non-small cell lung cancer stem cellsSemantic proximity Read ↗

Induction of a SALL4-dependency for targeted cancer therapySemantic proximity Read ↗

Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.